GREENFIELD, Ind., Oct. 1, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2025 financial results on Wednesday, November 5, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.
The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.aspx. A replay will also be available on the website shortly following the call.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
Investor Contact: Tiffany Kanaga (765) 740-0314 This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact: Colleen Parr Dekker (317) 989-7011 This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$21.49 |
| Daily Change: | -0.03 -0.14 |
| Daily Volume: | 7,146,276 |
| Market Cap: | US$10.680B |
November 05, 2025 October 24, 2025 September 23, 2025 August 27, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load